Could Ozempic-Like Drugs Help Slow Cancer Progression? New…

Could Ozempic-Like Drugs Help Slow Cancer Progression? New Study Suggests They Might TALMedora Health Desk Oncology | Obesity Medicine | Cancer Research Medications originally developed to treat type 2 diabetes and obesity may be showing promise in an entirely different area of medicine: cancer care. Researchers presenting new data at the American Society of Clinical Oncology (ASCO) annual meeting reported that GLP-1 receptor agonists, the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), may be associated with slower progression of several obesity-related cancers. While the findings are still early and do not prove cause and effect, they are adding to growing interest in the potential role of metabolic therapies in cancer treatment. Obesity is now recognized as a major risk factor for multiple cancers, including: Breast cancer Colorectal cancer Liver cancer Endometrial cancer Kidney cancer Pancreatic cancer Excess body fat can